Normal view MARC view ISBD view

Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi()).

MedStar author(s):

Citation: Journal of Foot & Ankle Surgery. 52(6):781-5, 2013 Nov-Dec.PMID: 23953278Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Case Reports | Journal Article | Research Support, N.I.H., ExtramuralSubject headings: *Enzyme Inhibitors/tu [Therapeutic Use] | *Janus Kinases/ai [Antagonists & Inhibitors] | *Polycythemia Vera/co [Complications] | *Pyrazoles/tu [Therapeutic Use] | *Skin Ulcer/dt [Drug Therapy] | *Wound Healing/de [Drug Effects] | Antimetabolites/ae [Adverse Effects] | Chronic Disease | Enzyme Inhibitors/pd [Pharmacology] | Humans | Hydroxyurea/ae [Adverse Effects] | Leg | Male | Middle Aged | Pyrazoles/pd [Pharmacology] | Skin Transplantation | Skin Ulcer/su [Surgery] | Wounds and Injuries/dt [Drug Therapy] | Wounds and Injuries/su [Surgery]Year: 2013 Local holdings: Available online through MWHC library: 2003 - present, Available in print through MWHC library:1999-2007ISSN:

1067-2516

Name of journal: The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle SurgeonsAbstract: We present the case of a 63-year-old white male with bilateral chronic leg ulcers due to polycythemia vera and hydroxyurea therapy who demonstrated dramatic healing of his wounds in response to ruxolitinib (Jakafi(), Novartis), a novel Janus kinase-1 and -2 inhibitor. This patient's wound had previously been refractory to multiple surgical interventions and immunosuppression. After the initiation of ruxolitinib, the patient underwent successful split-thickness skin grafting, with resultant healing of his wounds. He was stable without prednisone and other immunosuppressant therapy and had healed at 6 months. Ruxolitinib therapy could represent a novel option for patients who develop persistent inflammatory wounds in the setting of polycythemia vera and hydroxyurea therapy. Copyright 2013 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.All authors: Attinger CE, Dunning DM, Hubley KJ, Kallakury B, McNish S, Shanmugam VK, Shara N, Steinberg JSFiscal year: FY2014Digital Object Identifier:

http://dx.doi.org/10.1053/j.jfas.2013.07.003

Date added to catalog: 2014-08-21

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	23953278	Available		23953278

Available online through MWHC library: 2003 - present, Available in print through MWHC library:1999-2007

We present the case of a 63-year-old white male with bilateral chronic leg ulcers due to polycythemia vera and hydroxyurea therapy who demonstrated dramatic healing of his wounds in response to ruxolitinib (Jakafi(), Novartis), a novel Janus kinase-1 and -2 inhibitor. This patient's wound had previously been refractory to multiple surgical interventions and immunosuppression. After the initiation of ruxolitinib, the patient underwent successful split-thickness skin grafting, with resultant healing of his wounds. He was stable without prednisone and other immunosuppressant therapy and had healed at 6 months. Ruxolitinib therapy could represent a novel option for patients who develop persistent inflammatory wounds in the setting of polycythemia vera and hydroxyurea therapy. Copyright 2013 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.

English